Increasing use of anticoagulants in Germany and its impact on hospitalization for gastrointestinal bleeding.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 03 05 2019
revised: 08 07 2019
accepted: 12 07 2019
pubmed: 16 8 2019
medline: 14 2 2020
entrez: 16 8 2019
Statut: ppublish

Résumé

The aim of the study was to compare nationwide time trends of oral anticoagulant prescriptions with the time trend of gastrointestinal bleeding (GIB) in Germany from 2005 through 2016. The annual number of hospital admissions for GIB associated with gastric ulcers, duodenal ulcers, hematemesis, melena, hematochezia, and unspecified gastrointestinal bleeding (USGIH) was taken from the nationwide hospital referral file by the Federal Bureau of Statistics. The hospitalization rates were age-standardized using the German Standard Population 2011. The defined daily doses (DDD) of prescribed anticoagulants in outpatients for the same calendar period were taken from reports of the drug information system of the statutory health insurance. Based on DDD, drug treatment rates were calculated per 100,000 people. From 2005 to 2016, the annual anticoagulant prescription rates per 100,000 persons increased by 135.8% (from 901.4 to 2125.9). By 2011, direct oral anticoagulants (DOAC) accounted for <0.1% of all anticoagulants, but 49.9% in 2016. Over the same period, age-standardized hospital admissions for GIBs per 100,000 person-years decreased by 14% (from 128.89 to 110.87). Hospitalization rates for gastric ulcer and duodenal ulcer decreased steadily, and those for hematoma, melena and hematochezia continued to increase. Only the USGIH decreased from 2005 to 2011 (annual change of -3.35 (95% CI -5.44; -1.25) per 100,000 person-years) and subsequently increased (0.61, 95% CI -0,42; 1.65). Of all GIB cases, 5.8% received at least 6 red blood cell concentrates in 2005 and 4.6% in 2016. The two-phase time trend for USGIH was no longer present in this subgroup. Our nationwide comparison of outpatient OAC treatment rates and hospitalization rates for GIBs showed that GIB hospitalization rates declined despite increasing OAC treatment rates from 2005 to 2016. With increasing impact of DOACs after 2011, this decline was not affected.

Identifiants

pubmed: 31415939
pii: S0049-3848(19)30292-0
doi: 10.1016/j.thromres.2019.07.009
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

135-140

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Jan-Erik Guelker (JE)

Clinic of Cardiology, St.-Johannes-Hospital, Dortmund, Germany.

Dimitrios Ilousis (D)

Clinic of Cardiology, HELIOS Klinik Krefeld, Germany.

Knut Kröger (K)

Clinic of Vascular Medicine, HELIOS Klinik Krefeld, Germany. Electronic address: knut.kroeger@helios-kliniken.de.

Frans Santosa (F)

Medical Faculty Universitas Pembangunan Nasional Veteran Jakarta, Indonesia.

Bernd Kowall (B)

Institute for Medical Informatics, Biometry and Epidemiology, Germany.

Andreas Stang (A)

Institute for Medical Informatics, Biometry and Epidemiology, Germany; Department of Epidemiology, Boston University School of Public Health, 715 Albany St, Boston, MA 02118, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH